The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. (February 2021)

• Record Type: Journal Article
• Authors: Bruni, Cosimo; Guignabert, Christophe; Manetti, Mirko; Cerinic, Marco Matucci; Humbert, Marc
• Is Part Of: Lancet. Volume 3:Number 2(2021)
• Page Start: e149
• Page End: e159
• Publication Date: 2021-02
• Subjects: Rheumatology -- periodicals; 616.72305
• DOI: 10.1016/S2665-9913(20)30356-8
• Languages: English
• ISSNs: 2665-9913

Abstract

Summary: Cardiopulmonary complications are a leading cause of death in systemic sclerosis. Pulmonary hypertension in particular carries a high mortality and morbidity burden. Patients with systemic sclerosis can suffer from all of the clinical groups of pulmonary hypertension, particularly pulmonary arterial hypertension and pulmonary hypertension related to interstitial lung disease. Despite a similar pathogenetic background with idiopathic pulmonary arterial hypertension, different mechanisms determine a worse prognostic outcome for patients with systemic sclerosis. In this Viewpoint, we will consider the link between pathogenetic and potential therapeutic targets for the treatment of pulmonary hypertension in the context of systemic sclerosis, with a focus on the current unmet needs, such as the importance of early screening and detection, the absence of agreed criteria to distinguish pulmonary arterial hypertension with interstitial lung disease from pulmonary hypertension due to lung fibrosis, and the need for a holistic treatment approach to target all the vascular, immunological, and inflammatory components of the disease.